- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Summit Therapeutics PLC ADR (SMMT)
Summit Therapeutics PLC ADR stock price live, this page displays NASDAQ SMMT stock exchange data. View the SMMT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Summit Therapeutics PLC ADR real time stock price chart below.
What Is the Summit Therapeutics PLC ADR Stock Price Today?
The Summit Therapeutics PLC ADR stock price today is 15.780.
What Is the Stock Symbol for Summit Therapeutics PLC ADR?
The stock symbol for Summit Therapeutics PLC ADR is "SMMT."
What Stock Exchange Does Summit Therapeutics PLC ADR Trade On?
Summit Therapeutics PLC ADR is listed and trades on the NASDAQ stock exchange.
Is Summit Therapeutics PLC ADR a Good Stock to Buy?
Determining whether Summit Therapeutics PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SMMT quote. (ISIN: US86627T1088)
What Is the Summit Therapeutics PLC ADR Stock Price Today?
The Summit Therapeutics PLC ADR stock price today is 15.780.
What Is the Stock Symbol for Summit Therapeutics PLC ADR?
The stock symbol for Summit Therapeutics PLC ADR is "SMMT."
What Stock Exchange Does Summit Therapeutics PLC ADR Trade On?
Summit Therapeutics PLC ADR is listed and trades on the NASDAQ stock exchange.
Is Summit Therapeutics PLC ADR a Good Stock to Buy?
Determining whether Summit Therapeutics PLC ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SMMT quote. (ISIN: US86627T1088)
15.780
+0.210(+1.35%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.060
15.890
52 wk Range
12.070
29.230
SMMT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.06015.890
52 wk Range
12.07029.230
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SMMT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
30.221
Upside
+91.51%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
11 Buy
6 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 30.221
(+91.51% Upside)
Summit Therapeutics PLC ADR Earnings Call Summary for Q2/2026
- Summit posted Q2 loss of $0.37/share vs. $0.28 expected, a 32.6% miss; shares fell 4.6% after hours despite 1.6% regular-session gain.
- Cash rose to $690.7M from $598.7M in Q1 via $231M ATM raise; operating expenses jumped 24% to $151.8M on three Phase III trials.
- Updated HARMONi survival data showed 0.76 hazard ratio; company maintains Nov. 14, 2026 PDUFA date for ivonescimab in EGFR-mutated NSCLC.
- Key milestones: HARMONi-3 squamous PFS data H2 2026, OS interim analysis H1 2027, Arcus collaboration data mid-2027.
- Filed new $380M ATM facility for financing flexibility; commercial launch prep underway with leadership in place, field force hiring near approval.
Last Updated: 2026-07-23, 05:50 p/m
Read Full TranscriptEarnings
Latest Release
Jul 23, 2026
EPS / Forecast
-0.37 / -0.28
Revenue / Forecast
-- / --
Compare SMMT to Peers and Sector
Metrics to compare | SMMT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSMMTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.6x | −3.6x | −0.3x | |
PEG Ratio | 1.42 | −0.05 | 0.00 | |
Price/Book | 19.9x | 3.1x | 2.6x | |
Price / LTM Sales | - | 200.6x | 2.9x | |
Upside (Analyst Target) | 93.1% | 120.2% | 62.0% | |
Fair Value Upside | Unlock | 8.4% | 9.5% | Unlock |
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Summit Therapeutics PLC ADR (SMMT) Stock Price Today?
The Summit Therapeutics PLC ADR stock price today is 15.780 USD.
What Stock Exchange Does Summit Therapeutics PLC ADR Trade On?
Summit Therapeutics PLC ADR is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Summit Therapeutics PLC ADR?
The stock symbol for Summit Therapeutics PLC ADR is "SMMT."
What Is the Summit Therapeutics PLC ADR Market Cap?
As of today, Summit Therapeutics PLC ADR market cap is 12.450B USD.
What Is Summit Therapeutics PLC ADR's Earnings Per Share (TTM)?
The Summit Therapeutics PLC ADR EPS (TTM) is -1.12.
When Is the Next Summit Therapeutics PLC ADR Earnings Date?
Summit Therapeutics PLC ADR will release its next earnings report on Nov 11, 2026.
From a Technical Analysis Perspective, Is SMMT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Summit Therapeutics PLC ADR Stock Split?
Summit Therapeutics PLC ADR has split 0 times.
How Many Employees Does Summit Therapeutics PLC ADR Have?
Summit Therapeutics PLC ADR has 265 employees.
What is the current trading status of Summit Therapeutics PLC ADR (SMMT)?
As of Oct 20, 2026, Summit Therapeutics PLC ADR (SMMT) is trading at a price of 15.780 USD, with a previous close of 15.570 USD. The stock has fluctuated within a day range of 15.060 USD to 15.890 USD, while its 52-week range spans from 12.070 USD to 29.230 USD.
What Is Summit Therapeutics PLC ADR (SMMT) Price Target According to Analysts?
The average 12-month price target for Summit Therapeutics PLC ADR is 30.221 USD, with a high estimate of 43.6219317 USD and a low estimate of 12.00773746 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +91.51% Upside potential.
What Is the SMMT Premarket Price?
SMMT's last pre-market stock price is 15.500 USD. The pre-market share volume is 14,100.000, and the stock has decreased by -0.070, or -0.450%.
What Is the SMMT After Hours Price?
SMMT's last after hours stock price is 15.500 USD, the stock has decreased by -0.070, or -0.450%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.